Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Qlife announces that the company has CE-marked its PCR test for Sars-CoV-2 for professional use on the mobile test platform Egoo.Health and that the commercialization can begin immediately.
The current CE-mark applies to the professional use of the test platform Egoo.Health for sale on the European market. The next step is to place the COVID-19 test in strategic locations, where it can offer fast and reliable results with help from healthcare professionals.
"With this CE-marking, Qlife has achieved an important regulatory milestone. Our COVID-19-test is one of the first mobile PCR tests that can offer exactly the same clinical quality as laboratories. Now, we can really start the commercial rollout of our mobile test and make it available to a much larger target group and in environments where testing continuously must be done by healthcare professionals", says Thomas Warthoe, CEO of Qlife.
The CE-mark covers the test platform Egoo.Health, i.e. mobile test unit, disposable capsules and software. The CE-mark enables the commercialization to begin immediately.